Parcourir MS 2017 num. 11 par sujet "Récidive tumorale locale"
Voici les éléments 1-1 de 1
-
Chroniques génomiques - Immunothérapie « CAR-T » : une autorisation qui fait date
(Éditions EDK, Groupe EDP Sciences, 2017)The first therapy based on chimeric antigen receptors has been approved by the FDA. It gives excellent results in recurrent paediatric ALL; its cost is very high but fairly consistent with the clinical benefit (long term ...